Welcome to the OMA Blog

Medicare coverage of GLP-1s for weight loss indications will occur under the Medicare GLP-1 Bridge Model, rather than the BALANCE Model, through December 31, 2027. Eligible Medicare beneficiaries will continue to have access to covered GLP-1 medications nationwide with a fixed $50 copay through the extended Bridge Model. While the Bridge Model was originally scheduled to end December 31, 2026 – to be replaced by BALANCE on January 1, 2027 – CMS extended the Bridge Model to allow for ongoing coverage of GLP-1 medications given the delay of the BALANCE model. The extension of the Bridge Model will enable eligible Part D beneficiaries across the country to access covered GLP-1 medications through December 2027, regardless of their Part D plan sponsors’ participation decisions. CMS’ announced changes to Medicare coverage of GLP-1 medications are not expected to affect Medicaid coverage of the medications under the BALANCE model.

For Omosefe Ogbeifun, MD, MPH, medicine has always been about making a lasting difference. "For me, I’ve always been passionate about serving people. I feel healthcare gives me the opportunity to improve the health of people but also creates a positive, long-lasting impact in the lives of people" That passion is what first drew her to primary care. She enjoyed the continuity of care and the relationships she built with patients over time.

Obesity Pillars®, the official journal of the Obesity Medicine Association, has received an Impact Factor of 5.3 and a CiteScore of 7.8, indicators of the quality and influence among scholarly journals.

When Nidhi Sharma, MD, MPH, DABOM, was little, she had many questions about health that the adults around her couldn’t answer. Her family had a long history of strokes. As she watched many of them suffer from the condition, she wanted to know the cause. "I always asked my father, 'How did this happen? Why did this happen?'" she recalled. "He didn't know the answer, but he said, 'Maybe the doctor knows.'" His response stuck with her from that day forward and brought her to where she is today.

Long before she became a leader in obesity medicine in the United States, Miriam Zylberglait Lisigurski, MD, DABOM (better known to colleagues and patients as Dr. Z), was caring for patients as a physician in the Peruvian Navy.

When Meenal Shukla, MD, DABOM, began practicing family medicine in Brooklyn more than two decades ago, she expected to spend her days treating diabetes, hypertension, and other chronic illnesses.

Growing up in rural West Virginia, Mollie Cecil, MD, DABOM, FAAFP, experienced firsthand both the challenges and the strengths of small communities.

For Alina Elperin, MD, DABOM, medicine has always been about more than diagnosing and treating disease. As an internal medicine physician and Diplomate of the American Board of Obesity Medicine since 2016, her passion lies within prevention.

For the past decade, Al Robaina, MD, DABOM, has been helping patients as a board-certified internal medicine physician, helping patients with a variety of conditions such as hypertension, diabetes, and lipid disorders. But as he looked deeper at the root causes of many of those diseases, he realized there was one disease that seemed to be linked to them all: obesity.